REGN: Regeneron Pharmaceuticals, Inc. Company Current Liabilities

REGN (Regeneron Inc.) - company brandmark

Changes in the short-term loan amounts of Regeneron Pharmaceuticals (REGN) demonstrate liability management amid the development of innovations and partnerships, with the latest value recorded as 0.79. Stable demand for drugs makes the business a defensive asset against crises, while the localization of plants in the US minimizes transportation difficulties and cross-border risks.

REGN regeneron.com Company Short-Term Loans and Borrowings (07/04/2022 - 11/01/2026)

Analytical breakdowns for Regeneron Pharmaceuticals

- current quotes and average value forecast:
Price Chart Regeneron|REGN - Fair Value Consensus
- market capitalization information:
Market Valuation Regeneron Pharmaceuticals|REGN - Aggregate Business Value
- balance sheet net asset value indicators:
Net Assets per Single Share Regeneron|REGN - Accounting Value of Company|Market Capitalization to Book Value Ratio regeneron.com|REGN - Company Assets
- business debt structure and liquidity details:
Total Debt to Capital Regeneron Pharmaceuticals|REGN - Long-Term Indebtedness to Equity|Short-Term Debt to Capital Regeneron Pharmaceuticals|REGN - Company Cumulative Debt|Debt to Book Capitalization Ratio Regeneron Pharmaceuticals|REGN - Company Long-Term Indebtedness|Company Short-Term Debts Regeneron|Quick Liquidity regeneron.com
- earnings and multiples data:
REGN - Final Profit
Basic company analysis:REGN - Regeneron
Manufactured products of Regeneron Corp

The active growth of the innovative biologic portfolio of Regeneron Pharmaceuticals (REGN) requires precise liquidity management. An analysis of short-term balance sheet liabilities captures the cost of loans maturing within one year, reflecting the business's operational expenses. Daily data updates enable the tracking of fund movements without the delays associated with quarterly reports. The dynamics of this indicator, combined with revenue, determine the efficiency of working capital. Low volatility confirms the financial stability of Regeneron Pharmaceuticals (REGN).

Direct competitors

IRTC - Company Short-Term Debt|Company Short-Term Loans and Borrowings LNTH (Lantheus Holdings)|MLYS (Mineralys Therapeutics Inc) - Company Current Liabilities|HTFL: Amount of Current Liabilities|Company Short-Term Debt Kestra Medical Technologies|ESPR: Company Short-Term Loans and Borrowings|Company Short-Term Debts AMRN|AVR - Short-Term Debt|Company Short-Term Debts TNYA (Tenaya Therapeutics, Inc.)|Short-Term Indebtedness CVRx Inc|Milestone Pharmaceuticals - Company Short-Term Debts|Short-Term Debt Cardiol Therapeutics|HeartBeam (BEAT) - Company Short-Term Debt|Company Short-Term Indebtedness TENX|ADGM (Adagio Medical Holdings Inc.) - Company Short-Term Debts|Short-Term Debt BioCardia Inc BCDA|Company Short-Term Debt Catheter Precision (VTAK)|ABIO (arcabio.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debt Acasti Pharma Inc. ACST|Aerovate Therapeutics Inc. (AVTE) - Short-Term Debt|VERV - Company Short-Term Debt|WINT (Windtree Therapeutics) - Company Short-Term Indebtedness